NEWS DESK

IMRN Stock News, News Score & What It Could Mean

Immuron Limited - American Depositary Shares (IMRN) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.

HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
89/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$1.15
Trend Context
Mixed / range
Latest briefing

What's happening with IMRN

globenewswire.com16 Jul 2026

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com6 Jul 2026

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
accessnewswire.com22 Apr 2026

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026. The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
17 Apr 2026
Immuron Double Digit 3Q Sales Growth
Read ↗
Earnings news

IMRN earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
globenewswire.com16 Jul 2026

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

2
accessnewswire.com22 Apr 2026

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026. The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your IMRN research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK